**Treatment-Experienced
Patients With Prior Relapse
All Patients**

TABLE 107: SVR GENOTYPE 1 TREATMENT-EXPERIENCED WITH PRIOR RELAPSE: RELATIVE RISKS AND RISK DIFFERENCE FOR ALL TREATMENT COMPARISONS — RANDOM EFFECTS MODEL

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SIM12 PR24-48 RGT	PR48	2.49 (1.87 to 3.10)	45.12 (27.76 to 56.18)
B32 PR36-48 RGT		2.28 (1.43 to 3.11)	38.77 (13.53 to 56.52)
SOF12 + LDV12		2.91 (1.99 to 3.71)	58.98 (30.41 to 70.79)
PAR/RIT12 + OMB12 + DAS12		3.13 (2.43 to 3.83)	64.94 (46.06 to 72.34)
PAR/RIT12 + OMB12 + DAS12 + RBV12		3.08 (2.46 to 3.77)	63.33 (47.70 to 70.80)
SOF12 + LDV12 + RBV12		3.16 (2.58 to 3.87)	65.80 (52.86 to 72.67)
B32 PR36-48 RGT	SIM12 PR24-48 RGT	0.92 (0.59 to 1.28)	−6.18 (−32.61 to 17.44)
SOF12 + LDV12		1.18 (0.79 to 1.54)	13.86 (−16.37 to 33.26)
PAR/RIT12 + OMB12 + DAS12		1.25 (1.05 to 1.55)	19.31 (3.73 to 33.81)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.24 (1.07 to 1.50)	17.93 (5.54 to 30.95)
SOF12 + LDV12 + RBV12		1.27 (1.06 to 1.63)	20.50 (4.92 to 37.38)
SOF12 + LDV12	B32 PR36-48 RGT	1.28 (0.83 to 1.99)	19.60 (−12.71 to 45.76)
PAR/RIT12 + OMB12 + DAS12		1.37 (1.02 to 2.11)	25.62 (1.62 to 50.08)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.35 (1.03 to 2.07)	24.16 (1.99 to 48.48)
SOF12 + LDV12 + RBV12		1.38 (1.08 to 2.14)	26.58 (6.75 to 50.91)
PAR/RIT12 + OMB12 + DAS12	SOF12 + LDV12	1.06 (0.85 to 1.55)	5.31 (−14.30 to 34.00)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.04 (0.86 to 1.54)	3.81 (−13.40 to 32.95)
SOF12 + LDV12 + RBV12		1.07 (0.91 to 1.58)	6.13 (−8.93 to 35.48)
PAR/RIT12 + OMB12 + DAS12 + RBV12	PAR/RIT12 + OMB12 + DAS12	0.98 (0.84 to 1.19)	−1.48 (−15.03 to 14.96)
SOF12 + LDV12 + RBV12		1.01 (0.88 to 1.25)	0.71 (−11.56 to 18.95)
SOF12 + LDV12 + RBV12	PAR/RIT12 + OMB12 + DAS12 + RBV12	1.03 (0.89 to 1.22)	2.33 (−10.53 to 17.31)
Random effect model	Residual deviance	13.67 vs. 14 data points	
	Deviance information criteria	84.089	
Fixed effect model	Residual deviance	13.66 vs. 14 data points	
	Deviance information criteria	83.718	

ASU = asunaprevir; B = boceprevir; BEC = beclabuvir; CrI = credible interval; DAS = dasabuvir; DCV = daclatasvir; ELB = elbasvir; LDV = ledipasvir; OMB = ombitasvir; PAR = paritaprevir; PR = pegylated interferon plus ribavirin; q8 = every 8 hours; q12 = every 12 hours; RBV = ribavirin; RD = risk difference; RGT = response-guided therapy; RIT = ritonavir; RR = relative risk; SIM = simeprevir; SOF = sofosbuvir; SVR = sustained virologic response; T = telaprevir; vs. = versus.
Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.